FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Cardiovascular drug interactions in treatment of ischemic heart disease

Interakcije kardiovaskularnih lekova u terapiji ishemijske bolesti srca

Thumbnail
2008
1148.pdf (332.2Kb)
Authors
Vezmar, Sandra
Vučićević, Katarina
Miljković, Branislava
Article (Published version)
Metadata
Show full item record
Abstract
Treatment of ischaemic heart disease usually comprises concomitant use of several drugs and therefore, the potential of drug interactions in this patient population is substantial. If non-prescription drugs are reviewed, as well, it is clear that the efficacy and/or safety of therapy may be jeopardized in many patients. Studies show that much more attention should be paid to the problem of interactions and their consequences in clinical practice, since the majority of patients with ischaemic disease are prescribed at least one interacting combination of drugs. Due to knowledge and competencies it is primarily the role of pharmacist within the health care team, to identify and manage drug interactions in association with other health care professionals. It is also the role of pharmacist to educate the patient how to manage potential interactions appropriately. In this work, clinically significant cardiovascular drug interactions will be outlined as well as their underlying interaction m...echanism and management for providing efficient and safe pharmacotherapy.

Pacijenti sa ishemijskom bolesti srca često primenjuju više lekova istovremeno čime je potencijal lek-lek interakcija u ovoj populaciji značajan. Ukoliko se u razmatranje uzmu i lekovi koji se izdaju bez recepta, jasno je da su efikasnost i bezbednost farmakoterapije kod velikog broja pacijenata potencijalno ugrožene. Studije pokazuju da se problemu interakcija lekova i posledicama koje usled takvih interakcija mogu nastati, posvećuje nedovoljna pažnja u kliničkoj praksi, s obzirom da većina pacijenata na terapiji ishemijske bolesti srca primenjuje najmanje jednu kombinaciju lekova koji stupaju u interakciju. Kompetencije u identifikaciji i prevenciji klinički značajnih interakcija kardiovaskularnih i drugih lekova u značajnoj meri pripadaju farmaceutu u saradnji sa ostalim članovima zdravstvenog tima. Takođe je uloga farmaceuta da pacijentu pruži odgovarajuće informacije u cilju prevencije negativnih posledica interakcija. U okviru ovog rada biće detaljnije reči o klinički značajnim i...nterakcijama kardiovaskularnih lekova, mehanizmima njihovog nastanka kao i intervencijama neophodnim kako bi se obezbedila efikasna i bezbedna farmakoterapija.

Keywords:
interactions / cardiovascular drugs / interaction mechanism / pharmacist / interakcije / kardiovaskularni lekovi / mehanizam interakcija / farmaceut
Source:
Arhiv za farmaciju, 2008, 58, 5-6, 398-418
Publisher:
  • Savez farmaceutskih udruženja Srbije, Beograd

ISSN: 0004-1963

[ Google Scholar ]
Handle
https://hdl.handle.net/21.15107/rcub_farfar_1150
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/1150
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Vezmar, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1150
AB  - Treatment of ischaemic heart disease usually comprises concomitant use of several drugs and therefore, the potential of drug interactions in this patient population is substantial. If non-prescription drugs are reviewed, as well, it is clear that the efficacy and/or safety of therapy may be jeopardized in many patients. Studies show that much more attention should be paid to the problem of interactions and their consequences in clinical practice, since the majority of patients with ischaemic disease are prescribed at least one interacting combination of drugs. Due to knowledge and competencies it is primarily the role of pharmacist within the health care team, to identify and manage drug interactions in association with other health care professionals. It is also the role of pharmacist to educate the patient how to manage potential interactions appropriately. In this work, clinically significant cardiovascular drug interactions will be outlined as well as their underlying interaction mechanism and management for providing efficient and safe pharmacotherapy.
AB  - Pacijenti sa ishemijskom bolesti srca često primenjuju više lekova istovremeno čime je potencijal lek-lek interakcija u ovoj populaciji značajan. Ukoliko se u razmatranje uzmu i lekovi koji se izdaju bez recepta, jasno je da su efikasnost i bezbednost farmakoterapije kod velikog broja pacijenata potencijalno ugrožene. Studije pokazuju da se problemu interakcija lekova i posledicama koje usled takvih interakcija mogu nastati, posvećuje nedovoljna pažnja u kliničkoj praksi, s obzirom da većina pacijenata na terapiji ishemijske bolesti srca primenjuje najmanje jednu kombinaciju lekova koji stupaju u interakciju. Kompetencije u identifikaciji i prevenciji klinički značajnih interakcija kardiovaskularnih i drugih lekova u značajnoj meri pripadaju farmaceutu u saradnji sa ostalim članovima zdravstvenog tima. Takođe je uloga farmaceuta da pacijentu pruži odgovarajuće informacije u cilju prevencije negativnih posledica interakcija. U okviru ovog rada biće detaljnije reči o klinički značajnim interakcijama kardiovaskularnih lekova, mehanizmima njihovog nastanka kao i intervencijama neophodnim kako bi se obezbedila efikasna i bezbedna farmakoterapija.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Cardiovascular drug interactions in treatment of ischemic heart disease
T1  - Interakcije kardiovaskularnih lekova u terapiji ishemijske bolesti srca
VL  - 58
IS  - 5-6
SP  - 398
EP  - 418
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1150
ER  - 
@article{
author = "Vezmar, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2008",
abstract = "Treatment of ischaemic heart disease usually comprises concomitant use of several drugs and therefore, the potential of drug interactions in this patient population is substantial. If non-prescription drugs are reviewed, as well, it is clear that the efficacy and/or safety of therapy may be jeopardized in many patients. Studies show that much more attention should be paid to the problem of interactions and their consequences in clinical practice, since the majority of patients with ischaemic disease are prescribed at least one interacting combination of drugs. Due to knowledge and competencies it is primarily the role of pharmacist within the health care team, to identify and manage drug interactions in association with other health care professionals. It is also the role of pharmacist to educate the patient how to manage potential interactions appropriately. In this work, clinically significant cardiovascular drug interactions will be outlined as well as their underlying interaction mechanism and management for providing efficient and safe pharmacotherapy., Pacijenti sa ishemijskom bolesti srca često primenjuju više lekova istovremeno čime je potencijal lek-lek interakcija u ovoj populaciji značajan. Ukoliko se u razmatranje uzmu i lekovi koji se izdaju bez recepta, jasno je da su efikasnost i bezbednost farmakoterapije kod velikog broja pacijenata potencijalno ugrožene. Studije pokazuju da se problemu interakcija lekova i posledicama koje usled takvih interakcija mogu nastati, posvećuje nedovoljna pažnja u kliničkoj praksi, s obzirom da većina pacijenata na terapiji ishemijske bolesti srca primenjuje najmanje jednu kombinaciju lekova koji stupaju u interakciju. Kompetencije u identifikaciji i prevenciji klinički značajnih interakcija kardiovaskularnih i drugih lekova u značajnoj meri pripadaju farmaceutu u saradnji sa ostalim članovima zdravstvenog tima. Takođe je uloga farmaceuta da pacijentu pruži odgovarajuće informacije u cilju prevencije negativnih posledica interakcija. U okviru ovog rada biće detaljnije reči o klinički značajnim interakcijama kardiovaskularnih lekova, mehanizmima njihovog nastanka kao i intervencijama neophodnim kako bi se obezbedila efikasna i bezbedna farmakoterapija.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Cardiovascular drug interactions in treatment of ischemic heart disease, Interakcije kardiovaskularnih lekova u terapiji ishemijske bolesti srca",
volume = "58",
number = "5-6",
pages = "398-418",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1150"
}
Vezmar, S., Vučićević, K.,& Miljković, B.. (2008). Cardiovascular drug interactions in treatment of ischemic heart disease. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 58(5-6), 398-418.
https://hdl.handle.net/21.15107/rcub_farfar_1150
Vezmar S, Vučićević K, Miljković B. Cardiovascular drug interactions in treatment of ischemic heart disease. in Arhiv za farmaciju. 2008;58(5-6):398-418.
https://hdl.handle.net/21.15107/rcub_farfar_1150 .
Vezmar, Sandra, Vučićević, Katarina, Miljković, Branislava, "Cardiovascular drug interactions in treatment of ischemic heart disease" in Arhiv za farmaciju, 58, no. 5-6 (2008):398-418,
https://hdl.handle.net/21.15107/rcub_farfar_1150 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB